FOLH1 and Familial prostate cancer: 177Lu-PSMA-617 received FDA approval in March 2022 and its administration is indicated in patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with androgen-receptor pathway inhibitors and taxane-based chemotherapy [23].